This includes invasive pneumococcal disease and influenza. The primary aim of this study was to describe compliance with current Australian guidelines for vaccination of children and adolescents diagnosed with IBD. A secondary aim was to review the serological screening for VPD. Methods A random sample of patients (0-18 years at diagnosis), were selected from the Victoria Australia state based Pediatric Inflammatory Bowel Disease Register. A multi-faceted retrospective review of immunization status was undertaken, with hospital records audited, a telephone interview survey conducted with consenting parents and the vaccination history was checked against the primary care physician and Australian Childhood Immunization Register (ACIR) records. The routine primary childhood vaccinations and administration of the recommended additional influenza and pneumococcal vaccines was clarified. Results This 2007 audit reviewed the immunization status of 101individuals on the Victorian Pediatric IBD database. Median age at diagnosis was 12.1 years, 50% were on active immunosuppressive therapy. 90% (38/42) [95% confidence intervals (CI) 77%; 97%] with complete immunization information were up-to-date with routine primary immunizations. Only 5% (5/101) [95% CI 2%; 11%] received a recommended pneumococcal vaccine booster and 10% (10/101) [95% CI 5%; 17%] had evidence of having ever received a seasonal influenza vaccine. Those living in rural Victoria (p = 0.005) and younger at the age of diagnosis (p = 0.002) were more likely to have ever received an influenza vaccine Serological testing, reviewing historical protection from VPD, identified 18% (17/94) with evidence of at least one serology sample. Conclusion This study highlights poor compliance in IBD patients for additional recommended vaccines. A multi-faceted approach is required to maximize protection from VPD in this vulnerable special risk population. Keywords:
Crohn’s Disease – Professor Thomas Borody Of Australia Comes To New York To Discuss Significant New Findings
September figures show priority-one gastroenterology patients waited an average 47 days to be seen at the outpatient clinic – 50 per cent longer than the recommended 30-day maximum – and category-two patients waited an average 16 weeks. But waiting times have improved since a year ago, when some children waited up to a year to be assessed because of an acute shortage of gastroenterologists. It prompted the State Government to launch an urgent recruitment drive for specialists. The hospital says progress has been made after finding a gastroenterologist to fill a vacant position but it will have to take on more staff. A spokeswoman said PMH expected waiting times to improve further with a new part-time gastroenterologist due to start this month. Another 0.5 full-time equivalent position was in the appointment process and PMH was optimistic about appointing someone early next year. The Australian Medical Association welcomed the recent addition of a specialist but said it was clear more were needed to keep up with demand in the highly specialised area. WA president Richard Choong said gastroenterology was historically a difficult specialty to staff, which led to long delays for patients to be assessed and treated. “The fact PMH has managed to find someone recently and is close to more appointments is good news and very encouraging,” he said. “This is an area of medicine that is very specific and there are many conditions that need to access its services, but it’s a classic example of where there just aren’t enough people to do the jobs required.” Dr Choong said as a result many children were waiting too long, often in pain and discomfort, to be diagnosed and treated. “What I really hope is that the hospital will be able to recruit the extra staff it needs so children can be seen even more quickly,” he said.
Specialist to help ease wait times
Borody’s own patients, to his anti-mycobacteria therapy research. According to Prof. Borody’s report, as many as 95% of his patients have responded to treatment with full remission achieved by 65% of these patients. Dr. Borody says, “These results exceed all documented evidence of response to Crohn’s Disease therapies and promise significant relief for a large number of the estimated one million Crohn’s patients around the world.” Dr. Borody MD PhD FRACP, a graduate of the University of New South Wales, from which he holds a doctorate in medicine, will be presenting his findings in an open forum at: The Suffolk Y Jewish Community Center 74 Hauppauge Road in Commack, Long Island March 20, 2006 from 7-9 PM. Suggested donation $3 As the founder and current Medical Director of the Centre for Digestive Diseases (CDD), Dr. Borody has created a unique medical institution, internationally regarded for its novel approaches in research, diagnosis and the treatment of gastrointestinal conditions. He has been a recipient of the Winthrop Traveling Fellowship, the Neil Hamilton Fairly Fellowship and the Marshall & Warren Prize, and was a Clinical Fellow in Gastroenterology at the Mayo Clinic in Rochester in 1983. He is a member of the Australian Medical Association, the Gastroenterological Society of Australia, the European Gastroenterology Society, the Functional Brain-Gut Research Group and Fellow of the American College of Gastroenterology and the American College of Physicians. Prof. Borody supervises a number of major research programs as well as being involved as a reviewer for the American Journal of Gastroenterology, Digestive Diseases and Sciences, Endoscopy, Journal of Gastroenterology and Hepatology, Medical Journal of Australia and Digestive and Liver Diseases. He has published in excess of 120 scientific papers. In 2004 he was appointed an Adjunct Professor of the Faculty of Science at the University of Technology, Sydney. The Suffolk Y JCC is an agency of UJA Federation and affiliated with JCC Association.
check this out http://www.medicalnewstoday.com/releases/38664.php